文献速递甲状腺与浅表头颈介入US

超声引导射频消融治疗良性甲状腺结节2年随访结果

Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules: 2-Year Follow-Up Results From a Single Center.
PubMed 文献 · J Ultrasound Med · 2026-06-20

单中心前瞻性研究纳入200例患者共213个良性甲状腺结节行超声引导射频消融,按基线体积分为<5 mL、5-15 mL、>15 mL三组,随访24个月。主要评价指标为体积减少率、治疗成功率(VRR>50%)及并发症率。结果显示消融后结节持续显著缩小,24个月中位体积减少率达97.08%,治疗成功率92.3%-100%。

要点

  • 大结节早期缩小更快,6个月时>15 mL组体积减少率85.40%,显著高于<5 mL组59.51%和5-15 mL组64.33%(p=.001)。
  • 24个月时三组体积减少率趋于一致(97.67%、95.22%、98.53%),疗效无显著差异。
  • 总体并发症率2.5%,无严重不良事件;再生长率2.8%。

核心结论

  • 射频消融对良性甲状腺结节具有良好长期疗效,各体积组24个月时均达到可比的治疗成功率。
  • 较大结节初期缩小更快,较小结节呈渐进性缩小,最终疗效相当。

研究设计与样本

  • 单中心前瞻性研究,纳入200例患者共213个良性甲状腺结节,行超声引导射频消融。
  • 结节按基线体积分为三组:A组<5 mL(n=91),B组5-15 mL(n=95),C组>15 mL(n=27)。
  • 随访时间点为6、12、18、24个月,主要指标为体积减少率、治疗成功率(VRR>50%)及并发症率。

关键影像表现/征象

  • 消融后结节体积持续缩小,中位体积减少率从6个月的66.06%上升至24个月的97.08%。
  • 6个月时各组体积减少率呈现差异,大结节组缩小幅度明显大于中小结节组。
  • 24个月时不同基线体积组间的体积减少率差异消失,三组结果趋于一致。

诊断标准与关键数值

  • 治疗成功定义为体积减少率大于50%,本研究各时段治疗成功率为92.3%-100%。
  • 6个月各组体积减少率:A组59.51%,B组64.33%,C组85.40%,组间差异p=.001。
  • 24个月各组体积减少率:A组97.67%,B组95.22%,C组98.53%。
  • 再生长率为2.8%,总体并发症率为2.5%,无严重并发症发生。

临床应用与阅片要点

  • 对于基线体积较小的结节,应告知患者预期为渐进性缩小过程,避免因早期缩小不明显而误判疗效。
  • 随访中早期评估大结节可见明显体积减少,小结节则需更长时间观察才能评价最终疗效。
  • 报告随访体积减少时应注明结节基线体积分组,因早期体积减少速度与基线体积相关。

局限性

  • 该研究为单中心设计,样本量在各基线体积组间分布不均,>15 mL组仅27个结节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Ultrasound-guided radiofrequency ablation (RFA) is an effective alternative to surgery for benign thyroid nodules (BTNs). This study aimed to evaluate the 2-year clinical outcomes of RFA, focusing on volume reduction rate across different baseline volume strata.

METHODS: This single-center prospective study included 200 patients with 213 BTNs treated with RFA. Nodules were stratified into 3 groups based on baseline volume: Group A (<5 mL, n = 91), Group B (5-15 mL, n = 95), and Group C (>15 mL, n = 27). Clinical outcomes were assessed at 6, 12, 18, and 24 months. The primary metrics were the volume reduction rate (VRR), therapeutic success (VRR >50%), and complication rates.

RESULTS: RFA resulted in continuous and significant volume reduction. Median VRR increased from 66.06% at 6 months to 97.08% at 24 months. Distinct reduction patterns were observed: at 6 months, larger nodules (Group C) exhibited a higher VRR (85.40%) than Group A (59.51%) and Group B (64.33%) (p = .001). However, disparities narrowed over time. By 24 months, all groups achieved comparable outcomes (VRR: 97.67, 95.22, and 98.53%, respectively). Therapeutic success ranged from 92.3 to 100%. Regrowth occurred in 2.8% of cases. The complication rate was 2.5% with no major events.

CONCLUSION: RFA demonstrates favorable long-term efficacy. Larger nodules shrink faster initially, while smaller nodules reduce gradually but eventually achieve comparable success. Patients with smaller nodules should be counseled to expect a more gradual volume reduction process.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Sun, Huang, Zhang, et al. Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules: 2-Year Follow-Up Results From a Single Center. J Ultrasound Med. 2026. PMID: 42322197. doi:10.1002/jum.70346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。